ObsEva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.12.21	ObsEva Added to the NASDAQ Biotechnology Index (GlobeNewswire)
17.12.21	Pre-market Movers: GNFT, ABEO, SPRB, IO, CERN… (RTTNews)
17.12.21	ObsEva: Linzagolix Gets Positive CHMP Opinion For Uterine Fibroids - Quick Facts (RTTNews)
17.12.21	ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids (GlobeNewswire)
13.12.21	ObsEva Appoints Will Brown as Chief Financial Officer (GlobeNewswire)
10.12.21	ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021 (GlobeNewswire)
02.12.21	ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021 (GlobeNewswire)
22.11.21	Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
22.11.21	Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix (GlobeNewswire)
22.11.21	Obseva Announces Appointment of Stephanie Brown to its Board of Directors (GlobeNewswire)
04.11.21	ObsEva Announces Third Quarter 2021 Financial Results and Business Update (GlobeNewswire)
29.10.21	ObsEva Announces Management Change (GlobeNewswire)
20.10.21	ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo (GlobeNewswire)
19.10.21	ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo (GlobeNewswire)
13.10.21	ObsEva To Work With Syneos Health On Commercialization Of Linzagolix - Quick Facts (RTTNews)
13.10.21	ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix (GlobeNewswire)
30.09.21	ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer (GlobeNewswire)
15.09.21	ObsEva Submits NDA Of Linzagolix To FDA For Treatment Of Uterine Fibroids (RTTNews)
15.09.21	ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids (GlobeNewswire)
07.09.21	ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
05.08.21	ObsEva Announces Second Quarter 2021 Financial Results and Business Update (GlobeNewswire)
04.08.21	ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF (GlobeNewswire)
03.08.21	ObsEva to Present at Upcoming Investor Conferences (GlobeNewswire)
27.07.21	Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor (GlobeNewswire)
02.07.21	ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting (GlobeNewswire)
30.06.21	ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting (GlobeNewswire)
24.06.21	ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting (GlobeNewswire)
10.06.21	ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021 (GlobeNewswire)
02.06.21	ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 (GlobeNewswire)
31.05.21	ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021 (GlobeNewswire)
25.05.21	ObsEva Announces Proposed Changes to the Composition of its Board of Directors (GlobeNewswire)
20.05.21	ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of Yselty® (linzagolix) for the Treatment of Uterine Fibroids (GlobeNewswire)
06.05.21	ObsEva Announces First Quarter 2021 Financial Results and Business Update (GlobeNewswire)
06.05.21	ObsEva appoints Clive Bertram as Chief Commercial Officer (GlobeNewswire)
04.05.21	ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain (GlobeNewswire)
30.04.21	ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021 (GlobeNewswire)
27.04.21	ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants (GlobeNewswire)
22.04.21	ObsEva Annual General Meeting 2021 (GlobeNewswire)
05.03.21	ObsEva Announces Year End 2020 Financial Results and Business Update (GlobeNewswire)
03.03.21	ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference (GlobeNewswire)
17.02.21	ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference (GlobeNewswire)
11.02.21	ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares (GlobeNewswire)
10.02.21	ObsEva Provides Business Outlook for 2021 (GlobeNewswire)
28.01.21	ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares (GlobeNewswire)
19.01.21	Pre-market Movers In Healthcare Sector: DBVT, ZOM, OBSV, BNGO, NVCN… (RTTNews)
15.01.21	Pre-market Movers In Healthcare Sector: DBVT, OBSV, APYX... (RTTNews)
11.01.21	ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program (GlobeNewswire)
07.01.21	ObsEva SA to Participate in JP Morgan Virtual Healthcare Conference January 11 - 14, 2021 (GlobeNewswire)
04.01.21	ObsEva appoints David Renas as Chief Financial Officer (GlobeNewswire)
10.12.20	ObsEva Announces Additional Phase 3 PRIMROSE 1 and 2 Study Results Confirming Sustained Efficacy and Continued Safety of linzagolix in the Treatment of Uterine Fibroids (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

27.09.24		Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester
27.09.24		SPI aktuell: SPI klettert
24.09.24		Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen
23.09.24		Gewinne in Zürich: SPI bewegt schlussendlich im Plus
23.09.24		Gute Stimmung in Zürich: SPI notiert im Plus
21.08.24		Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus
15.08.24		Börse Zürich in Grün: SPI legt zum Handelsende zu
15.08.24		Börse Zürich in Grün: SPI in der Gewinnzone

27.09.24

Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester

27.09.24

SPI aktuell: SPI klettert

24.09.24

Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen

23.09.24

Gewinne in Zürich: SPI bewegt schlussendlich im Plus

23.09.24

Gute Stimmung in Zürich: SPI notiert im Plus

21.08.24

Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus

15.08.24

Börse Zürich in Grün: SPI legt zum Handelsende zu

15.08.24

Börse Zürich in Grün: SPI in der Gewinnzone

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Sonova Hldg	309.80	1.91 %	K V
Part Grp Hldg	1’251.00	1.87 %	K V
Geberit	524.40	1.51 %	K V
Novartis	92.89	1.45 %	K V
Roche Hldg G	254.30	1.27 %	K V
Zurich Insur Gr	548.60	0.18 %	K V
Swiss Life Hldg	728.20	0.14 %	K V
Nestle	76.04	0.11 %	K V
UBS Group	28.16	0.07 %	K V
Kuehne+Nagel Int	207.60	-0.19 %	K V

Nachrichten zu ObsEva AG

Aktien Top/Flop

ObsEva Peer Group Nachrichten

Meistgelesene Nachrichten